B. Metzler seel. Sohn & Co. Holding AG Takes $3.28 Million Position in Avantor, Inc. (NYSE:AVTR)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Avantor, Inc. (NYSE:AVTR - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 126,855 shares of the company's stock, valued at approximately $3,282,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc grew its position in Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company's stock worth $25,000 after purchasing an additional 1,102 shares during the last quarter. Blue Trust Inc. increased its position in Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company's stock valued at $31,000 after acquiring an additional 1,391 shares during the period. UMB Bank n.a. acquired a new position in Avantor during the 3rd quarter worth $49,000. Nisa Investment Advisors LLC grew its stake in shares of Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock worth $53,000 after purchasing an additional 835 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock valued at $70,000 after purchasing an additional 1,285 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of the company's stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares in the company, valued at approximately $740,372.64. This represents a 10.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on AVTR. Morgan Stanley boosted their price target on shares of Avantor from $28.00 to $29.00 and gave the stock an "overweight" rating in a research report on Monday, July 29th. TD Cowen lifted their price target on Avantor from $28.00 to $31.00 and gave the company a "buy" rating in a research report on Monday, July 29th. UBS Group cut their price objective on Avantor from $30.00 to $29.00 and set a "buy" rating for the company in a report on Tuesday, October 8th. Stifel Nicolaus lifted their target price on Avantor from $27.00 to $28.00 and gave the stock a "buy" rating in a report on Monday, July 29th. Finally, Barclays cut their price target on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Friday, October 25th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $27.57.

Avantor Trading Up 2.1 %

Shares of NYSE:AVTR opened at $20.14 on Thursday. The firm has a fifty day moving average of $24.14 and a two-hundred day moving average of $23.91. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. Avantor, Inc. has a 12-month low of $19.49 and a 12-month high of $28.00. The firm has a market capitalization of $13.71 billion, a P/E ratio of 43.78, a price-to-earnings-growth ratio of 2.39 and a beta of 1.35.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.